John C. Bell, Ph.D., CLIP InvestigatorOttawa Hospital Research Institute (Canada)

Our vision is to create a novel therapeutic virus that will work in synergy with some of the exciting new discoveries supported by the CRI...
Area of Research: All Cancers

Immunotherapy, especially checkpoint blockade, typically works better against “foreign-looking” tumors, but some tumors can survive by disguising themselves from the immune system. Dr. Bell is exploring how we can make tumors appear more foreign by introducing a Vaccinia virus (VacV). VacV is designed to kill tumor cells directly while simultaneously promoting anti-cancer immune responses. Vaccinia virus has already shown effectiveness against liver cancer, and Dr. Bell aims to improve its anti-tumor abilities. By mixing up VacV’s genes and generating different strains, he is seeking the combination of virus genes that maximizes both the tumor-killing and immune-stimulating capabilities of the virus, while minimizing its ability to infect normal, healthy cells.

Our vision is to create a novel therapeutic virus that will work in synergy with some of the exciting new discoveries supported by the CRI, thus making immunotherapies more effective in a broader range of patients.

Projects and Grants

Bio-engineering an Oncolytic Vaccinia Virus to Augment the Anti-Tumour Immune Response in Human Cancers

Ottawa Hospital Research Institute (Canada) | All Cancers | 2016

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top